MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Details

Serval ID
serval:BIB_1E3C16F37527
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
Journal
Neuro-oncology
Author(s)
Mansouri A., Hachem L.D., Mansouri S., Nassiri F., Laperriere N.J., Xia D., Lindeman N.I., Wen P.Y., Chakravarti A., Mehta M.P., Hegi M.E., Stupp R., Aldape K.D., Zadeh G.
ISSN
1523-5866 (Electronic)
ISSN-L
1522-8517
Publication state
Published
Issued date
14/02/2019
Peer-reviewed
Oui
Volume
21
Number
2
Pages
167-178
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.
Keywords
DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Gene Expression Regulation, Neoplastic, Glioblastoma/diagnosis, Glioblastoma/genetics, Glioblastoma/therapy, Humans, Prognosis, Promoter Regions, Genetic, Tumor Suppressor Proteins/genetics, MGMT, diagnostic, glioma, methylation, molecular markers, prognostic
Pubmed
Web of science
Open Access
Yes
Create date
12/09/2018 13:54
Last modification date
27/04/2020 6:20
Usage data